News

MONTREAL, QUEBEC-- - MethylGene Inc. today announced financial results for the second quarter ended June 30, 2010. In addition, the Company provided a clinical trial update for its multi-targeted kinase oncology inhibitor, MGCD265.

Nuvo Research Inc. , a drug development company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the quarter ended June 30, 2010.

Aeterna Zentaris Inc. , a late-stage drug development company specialized in oncology and endocrinology, today announced that its President and CEO, Juergen Engel, Ph.D., will present a corporate overview at the upcoming 9th Annual Needham Healthcare Conference on Thursday, June 10, 2010 at 3:20 p.m. in the Henry Room of the New York Palace Hotel in New York City.

MONTREAL, CANADA-- - Theratechnologies

TORONTO, ONTARIO-- - Lorus Therapeutics Inc. , a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, announced today that it filed a Registration Statement on Form F-1 with the United States Securities and Exchange Commission for an offering of up to US$17,500,000 of units in the United States.

MONTREAL, QUEBEC-- - Ambrilia Biopharma Inc. announced today that, as a result of the closing of the initial phase of the transaction disclosed on May 26, 2010, Ambrilia and its subsidiary Cellpep Pharma Inc. have obtained today non-dilutive financing of approximately $2M.